Back to search results

Observational Study of EIM for ALS

This study is looking at a device called Electrical Impedance Myography (EIM) to see if it can help track the progression of Amyotrophic Lateral Sclerosis (ALS). EIM uses a gentle electrical current to measure signals in your muscles. Researchers want to see if changes in these EIM measurements over 8 months can serve as a useful "biomarker" (a measurable indicator of a disease's presence or severity) for ALS. This could help doctors and researchers better understand how ALS is progressing and how well new treatments are working. You might be able to join if you are 18 or older, have a diagnosis of ALS (clinically possible, probable, lab-supported probable, or definite), and your ALS symptoms started within the last 36 months. You also need to have good lung function (Vital Capacity of at least 40%). The study aims to enroll 80 participants.

Study design
This is an observational study, meaning researchers will be watching and collecting information without giving any new treatments. It plans to include 80 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, EIM phase change, is measured over 8 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06491732

EIM Via the Myolex mScan as an ALS Biomarker

Recruiting
Not specifiedAges 18+Observational
Beth Israel Deaconess Medical Center
~80 participants
Updated 2026-04-22 on ClinicalTrials.gov
What's tested:Electrical Impedance Myography

At a glance

Recruiting sites
6 of 6 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
EIM phase change over time
Measured over 8 months

Conditions

Amyotrophic Lateral Sclerosis

Explore related trials

Amyotrophic Lateral Sclerosis

NCT06491732

Where you'd take part

This study runs at 6 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Atrium Health Wake Forest Baptist Medical Center

    Winston-Salem, North Carolinastudy coordinator listed

    Recruiting

  • Barrow Neurological Institute

    Phoenix, Arizonastudy coordinator listed

    Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusettsstudy coordinator listed

    Recruiting

  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshirestudy coordinator listed

    Recruiting

  • Massachusetts General Hospital

    Boston, Massachusettsstudy coordinator listed

    Recruiting

  • University of Michigan

    Ann Arbor, Michiganstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Seward Rutkove, MD · PRINCIPAL_INVESTIGATOR · Beth Israel Deaconess Medical Center
  • Masumeh Hatami, MD · STUDY_DIRECTOR · Beth Israel Deaconess Medical Center

Who to contact

Giulia Cenci
[email protected]
617-667-3056
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Sporadic or familial ALS diagnosed as clinically possible, probable, lab-supported probable, or definite ALS defined by revised El Escorial criteria
Capable of providing informed consent and complying with study procedures in the investigator's opinion
Time since ALS symptom onset ≤36 months
Vital Capacity of ≥40% of predicted capacity as measured by forced vital capacity or slow vital capacity
Must have a study partner for home visits
Access to the internet for data upload
Age 18 years or older

Exclusion

Clinically significant unstable medical condition (other than ALS) that would affect the participant's ability to participate, according to the investigator's judgment
Patient with pure upper motor neuron disease (PLS)
Known history of unstable psychiatric disease, cognitive impairment, dementia, or active substance abuse
Significant pitting edema (2+ or more) that would interfere with EIM measures
Active cancer or history of cancer treated with chemotherapy and/or radiation
BMI \>35

What this trial measures

  • EIM phase change over time8 months

    Mean and standard deviation in rate of change in EIM phase values compared to mean and standard deviation in rate of change in ALSFRS-R over 8 months